Combination Therapies Targeting the PI3K/AKT/mTOR Pathways

Aung Naing, Gordon B. Mills, Funda Meric-Bernstam

Research output: Chapter in Book/Report/Conference proceedingChapter


The phosphoinositide 3-kinase (PI3K) pathway was first described by Lewis C. Cantley’s group in 1998 (Fruman et al. in Annu Rev Biochem 67:481–507, 1998, [1]; Cantley in Science 296(5573):1655–1657, 2002, [2]). Upon activation, PI3K signaling can act on diverse downstream substrates (Cantley in Science 296(5573):1655–1657, 2002, [2]; Laplante and Sabatini in Cell 149(2):274–293, 2012, [3]). The PI3K pathway that includes AKT and mTOR contributes to many events that are critical for normal and pathophysiological cell metabolism, regulation of gene expression, cytoskeletal rearrangement, and cell survival.

Original languageEnglish (US)
Title of host publicationCancer Drug Discovery and Development
PublisherHumana Press Inc.
Number of pages30
StatePublished - 2016
Externally publishedYes

Publication series

NameCancer Drug Discovery and Development
ISSN (Print)2196-9906
ISSN (Electronic)2196-9914


  • Drug resistance
  • Dual inhibitors
  • Feedback loops
  • Predictors of response
  • Regulators of PI3K/AKT/mTOR pathway
  • Targeted therapies

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Cancer Research


Dive into the research topics of 'Combination Therapies Targeting the PI3K/AKT/mTOR Pathways'. Together they form a unique fingerprint.

Cite this